Tyler Xiu

Tyler Xiu
Of Counsel

Edinburgh Tower, 33/F

Hong Kong, China

txiu@mofo.com

852 25850778

REGIONS

China

BAR ADMISSIONS

New York

Hong Kong

EDUCATION

Soochow University, LL.B.

Cornell Law School, LL.M.

Georgetown University, M.Sc.

Tyler’s practice encompasses various aspects of transactional, regulatory, and contentious IP matters including technology transfer and licensing, IP and data-driven strategic cooperation, technical services and outsourcing arrangements, technology/IP-related advice in cross-border M&A and PE transactions, cybersecurity and data privacy, telecommunications regulation, pharmaceutical regulation, and patent protection. He advises a diverse range of multinational companies mainly in the life sciences, IT, telecommunications, manufacturing, and financial industries. In the words of his clients, “Tyler Xiu is an excellent up-and-coming lawyer, who is very proactive and helpful.” (The Legal 500 Asia Pacific).

Tyler is fluent in Chinese and English.

Representative Experience

  • Advising Ensem Therapeutics, Inc., a biotechnology company focusing on high value and difficult-to-drug oncology targets, on its partnership with BeiGene, Ltd., a global biotechnology company, for BeiGene to acquire an exclusive global license to an Investigational New Drug (IND) application-ready oral cyclin-dependent kinase 2 (CDK2) inhibitor. Under the terms of the agreement, ENSEM will receive an upfront payment, and will be eligible for additional payments upon the achievement of certain development, regulatory, and commercial milestones, totaling up to $1.33 billion, in addition to tiered royalties.
  • Advising Jamieson Laboratories Ltd. and its parent company Jamieson Wellness Inc. (TSX:JWEL) in their partnership with DCP Capital, a leading international private equity firm founded by experienced private equity investors in Greater China. Through this transaction, DCP contributed US$35 million in exchange for a 33% interest in the Company’s Chinese operations and made a US$75 million preferred share investment in the Company.
  • Counseling a U.S. medical device company that focuses on the research, development, production, and marketing of respiratory care devices and services, in its engagement by a PRC medical device company for commissioned development of automatic high flow ventilators, including the associated technology licensing arrangements.
  • Advising a U.S. biopharmaceutical company on its strategic collaboration with a Chinese pharmaceutical company to develop and commercialize a bi-functional fusion protein inhibiting immune checkpoint and activating natural killer (NK) cells for the treatment of solid tumors, in the Asia Pacific Ex-Japan region.
  • Advising a leading pan-Asian retailer in Hong Kong on:
    • A technology license agreement and joint venture with a digital retail platform for the purposes of providing online retailers with operational processes, marketing, supply, payment, merchandise, e-commerce, and customer services; and
    • Its licensing of technology and trademarks and provision of technical services in relation to the establishment of a joint venture for the purposes of developing a market-leading independent multi-partner coalition loyalty program for the ASEAN markets, and also the data privacy and data security issues under PRC law and cross-border data transfer issues that involve multiple jurisdictions in Asia. 
  • Advising an online game platform and game creation system on its trailblazing joint venture with another company to establish and launch the game platform in China, which would be the first foreign online game platform with user-generated games and revenue-sharing to obtain a government license in the PRC. 
  • Advising a leading Chinese investment fund on its strategic partnership with a leading U.S. IT software company to establish the financial cloud infrastructure for the People’s Bank of China, key state banks, and the governments of various major cities.
  • Assisting a leading global digital library with the amendment of its license agreement with a Chinese Internet technology company, under which the tech company is granted a license to allow users to access the client’s digital library of sheet music.
  • Advising a PRC advanced semiconductor materials company on obtaining a technology license and associated support services from a German specialty chemicals and equipment company, with respect to chemicals for wafer level packaging and wafer level semiconductor interconnect.

Rankings

Recommended China: Life Sciences and Healthcare: Foreign Firms

Legal 500 Asia Pacific 2025

Recommended China FinTech: Foreign Firm

Legal 500 Asia Pacific 2021,2023

Recommended China Healthcare and Life Sciences: Foreign Firms

Legal 500 Asia Pacific 2021

Recommended Hong Kong Intellectual Property

Legal 500 Asia Pacific 2021

Recommended Hong Kong TMT

Legal 500 Asia Pacific 2021 - 2024

Recommended: China TMT: Foreign Firms

Legal 500 Asia Pacific 2022-2023

Recommended: China: Intellectual Property: Foreign Firms

Legal 500 Asia Pacific 2023